Celltrion Healthcare Co Ltd
KOSDAQ:091990

Watchlist Manager
Celltrion Healthcare Co Ltd Logo
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Watchlist
Price: 75 900 KRW -5.6% Market Closed
Market Cap: 12.5T KRW
Have any thoughts about
Celltrion Healthcare Co Ltd?
Write Note

Celltrion Healthcare Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Healthcare Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Healthcare Co Ltd
KOSDAQ:091990
Net Income (Common)
â‚©136B
CAGR 3-Years
-8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
C
Chorokbaem Healthcare Co Ltd
KRX:118000
Net Income (Common)
-â‚©14.5B
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
W
WSI Co Ltd
KOSDAQ:299170
Net Income (Common)
â‚©2.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Wonik Co Ltd
KOSDAQ:032940
Net Income (Common)
-â‚©4.9B
CAGR 3-Years
N/A
CAGR 5-Years
43%
CAGR 10-Years
N/A
H
HLB Life Science Co Ltd
KOSDAQ:067630
Net Income (Common)
-â‚©9.2B
CAGR 3-Years
48%
CAGR 5-Years
11%
CAGR 10-Years
-15%
B
BlueMTec Co Ltd
KOSDAQ:439580
Net Income (Common)
-â‚©2.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Celltrion Healthcare Co Ltd
Glance View

Market Cap
12.2T KRW
Industry
Health Care

Celltrion Healthcare Co., Ltd. is a pioneering biopharmaceutical company based in South Korea, with a remarkable focus on developing and manufacturing innovative therapies that harness the power of biotechnology. Established in 2002, Celltrion has rapidly emerged as a leader in the biopharmaceutical industry, particularly known for its biosimilars and monoclonal antibody products. The company's mission is rooted in making high-quality medications more accessible and affordable on a global scale, targeting serious diseases such as cancer, autoimmune disorders, and infectious diseases. With a robust pipeline of biosimilar products aimed at offering effective alternatives to expensive biologics, Celltrion is strategically positioned to capitalize on the growing demand for cost-effective pharmaceutical solutions, especially as patent expirations of original biologics pave the way for increased competition in the market. What sets Celltrion apart is its commitment to research and development, supported by its state-of-the-art manufacturing facilities that comply with international quality standards. Its flagship products, including trastuzumab biosimilars, have already garnered approval and are being successfully marketed in multiple regions, including Europe and Asia. By leveraging cutting-edge biomanufacturing techniques and its extensive expertise, Celltrion not only reduces reliance on traditional pharmaceuticals but also addresses pressing healthcare needs globally. For investors, Celltrion presents a compelling opportunity as it continues to expand its global footprint, with increasing partnerships and collaborations aiming to unlock new markets and enhance shareholder value. As the biopharmaceutical landscape evolves, Celltrion’s innovative approach and steadfast growth trajectory position it as a formidable player, making it a company worth watching for anyone interested in the future of healthcare.

Intrinsic Value
64 279.29 KRW
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Celltrion Healthcare Co Ltd's Net Income (Common)?
Net Income (Common)
136B KRW

Based on the financial report for Jun 30, 2023, Celltrion Healthcare Co Ltd's Net Income (Common) amounts to 136B KRW.

What is Celltrion Healthcare Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
1%

Over the last year, the Net Income (Common) growth was -3%. The average annual Net Income (Common) growth rates for Celltrion Healthcare Co Ltd have been -8% over the past three years , 1% over the past five years .

Back to Top